Eli Lilly announced that its Alzheimer’s drug Donanemab showed “significant slowing of decline” in cognitive and daily function in patients with early symptomatic Alzheimer's disease. The results were based on Phase 2 (mid-stage) clinical trials with 272 participants. A timeline for Phase 3 (late-stage) trials has not yet been announced.
Extra: Over 5M Americans are currently living with Alzheimer’s (projected to reach nearly 14M by 2050).
The New Paper
This story is from the January 12, 2021 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.
